Exicure, a biotechnology company, announced board changes effective June 30, 2026. Director Ham Jung Kyu resigned, and the board expanded from five to six members. Two new directors—Go Jin Young and Han Eui Seok—were appointed as Class III directors. The company also formed a Compensation Committee, with Han as Chair and Dongho Lee as a member.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding EXICURE INC (XCUR)?

Major stakeholders currently include Carlyle Group Inc. ($239.6K), Geode Capital Management, LLC ($157.6K), Vanguard Capital Management LLC ($140.8K). Based on the latest 13F filings, there are a total of 18 tracked investment funds and institutions maintaining positions in XCUR.

What is the overall institutional sentiment toward XCUR recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $116.0K, driven by 7 managers accumulating shares while 4 reduced their exposure.

Which institutions have been selling or reducing their XCUR positions?

In the latest period, 2 funds trimmed their holdings, and 2 managers completely exited their positions. The aggregate reported sell value was $27.4K.

Are there any notable investors adding XCUR to their portfolios?

Yes, buying activity remains notable. 4 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $200.1K.